Clinical trial regulation looks bureaucratic from outside the industry and complicated from inside it. The 2026 picture is shaped by three overlapping frameworks, each with its own expectations for how an investigational medicinal product gets packaged, labeled, shipped, and dispensed at trial sites. Most sponsors know the frameworks exist. Fewer have a concrete picture of how they shape the packaging side.
EU Clinical Trials Regulation (CTR) 536/2014
In force since January 2022, fully applicable in 2026. Centralizes EU clinical trial applications via the Clinical Trials Information System (CTIS). The packaging-relevant requirements:
- IMP labeling has to satisfy specific content requirements: sponsor, protocol number, trial reference, IMP identifier, storage conditions, expiry, batch number, randomization code where applicable.
- Blinding documentation has to be reconstructable for unblinding.
- Multi-language patient information for trials across EU member states (typically booklet labels rather than separate cartons per language).
- Supply chain transparency in CTIS.
FDA 21 CFR Part 312
The US framework for Investigational New Drug applications. Part 312.6 specifically governs IMP labeling and packaging. Key requirements:
- Caution statement ("Caution: New Drug, Limited by Federal law to investigational use") on every label.
- Investigator and study identification.
- Compliance with cGMP standards from 21 CFR 210/211 for the manufacturing and packaging operations.
- Investigator brochure references where the label can't carry full information.
ICH GCP guidelines
International Council for Harmonisation Good Clinical Practice. Not regulation in itself, but the standard regulators use to evaluate trial conduct. Affects the packaging side through:
- Storage requirements at sites (validated conditions, controlled access).
- Drug accountability (every unit dispensed and returned must be traceable).
- Excursion reporting (any deviation from storage conditions reported to sponsor).
What this means for the wallet design
The packaging side of clinical trial regulation lives in three places:
Label content and language. Booklet labels for multi-language trials. Sponsor, protocol, IMP identifier, randomization code, all in the right places, in the right languages. Our clinical trial packaging service includes booklet label production as standard.
Randomization integrity. The pack design has to keep blinded products distinguishable to the IRT system but indistinguishable to the patient. That's a real engineering problem when active and placebo have different physical properties.
Drug accountability. Every wallet has a unique identifier that flows from manufacture through dispensing to return. The 2D Data Matrix code is part of this, plus the wallet itself has to support per-unit tracking.
Where trials get into trouble
Three patterns we see:
- Label translation issues caught at site activation, delaying recruitment.
- IRT integration that doesn't scan reliably across all sites.
- Insufficient blinding (the active wallet looks subtly different from the placebo wallet, which a clever site coordinator notices).
Solving these problems is iterative work between the sponsor, the IRT system vendor, and the packaging partner. Not a one-time spec lock.
If you're scoping packaging for a clinical trial
The right time to involve the packaging partner is during protocol design, not after the trial sites are selected. Protocol decisions ripple into packaging decisions in ways that are expensive to retrofit.
Send us the protocol and we'll work through the regulatory implications and come back with a packaging concept and a timeline.
Request a free sample now!
